StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) company profile

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

About Travere Therapeutics

Pharmaceutical Preparations, SIC 2834

This biopharmaceutical company identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its commercial product portfolio includes sparsentan, marketed as FILSPARI, an oral medication approved to reduce the decline of kidney function in adults with primary Immunoglobulin A nephropathy. The company also markets tiopronin tablets, under the brand names Thiola and Thiola EC, to treat cystinuria, a rare genetic disorder that causes recurring kidney stones. Additionally, the company advances clinical-stage candidates such as sparsentan for focal segmental glomerulosclerosis and pegtibatinase for classical homocystinuria. It provides these treatments to patient populations with severe, unmet medical needs.

The company is headquartered in San Diego, California. Beyond its domestic operations, its approved therapies have gained regulatory marketing authorization across member states of the European Union, Iceland, Liechtenstein, Norway, and the United Kingdom, alongside commercial distribution launched in Germany and Austria. The firm also relies on regional partnerships to develop and commercialize treatments across international markets including Japan, South Korea, and Taiwan.

Summary of the business section of Travere Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Travere Therapeutics, Inc.
Headquarters
San Diego, CA
Address
3611 Valley Centre Dr, Suite 300 92130
Phone
(888) 969-7879
Employees
497, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
California
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
TVTX
Former tickers
RTRX until Jan 11, 2021
Exchange
Nasdaq
IPO date
Nov 8, 2012
Shares outstanding
94M, Jul 30, 2026
Public float
$1.31B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1438533
CUSIP
89422G107
ISIN
US89422G1076
FIGI
BBG000P9D6W9
Share class FIGI
BBG001SL72C5
EIN
26-2383102

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric M. DubeCHIEF EXECUTIVE OFFICER, Director432,886
Peter HeermaEVP, CHIEF COMMERCIAL OFFICER117,066
Elizabeth E. ReedChief Legal Officer and GC142,889
Jula InrigEVP, Head of R&D & CMO102,491
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER47,728
William E. RoteChief Research Officer98,197
Christopher R. ClineCHIEF FINANCIAL OFFICER87,908
Jeffrey A. MecklerDirector109,800
Gary A. LyonsDirector62,400
Roy D. BaynesDirector46,000
Timothy CoughlinDirector56,250
Brinkley Ruth WilliamsDirector29,750
Suzanne Louise BruhnDirector32,750
Ron SquarerDirector39,375
Sandra PooleDirector34,000
John A. OrwinDirector39,375

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$8.46M$24.50M$2.45M$140$125
FY2025$5.20M$10.95M$1.55M$123$118
FY2024$7.57M$885.49K$2.01M$63$119
FY2023$5.75M$687.24K$2.24M$148$114
FY2022$5.74M$6.56M$2.14M$219$126
FY2021$5.45M$10.29M$1.64M$192$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Eric Dube, Ph.D.
President, Chief Executive Officer and Director
$854.25K$3.31M$3.31M$964.13K$14.87K$8.46M+62%
Christopher Cline
Chief Financial Officer
$522.92K$583.11K$738.25K$393.75K$12.89K$2.25M+50%
Peter Heerma
Chief Commercial Officer
$527.92K$583.11K$738.25K$397.50K$14.98K$2.26M+49%
Jula Inrig, M.D.
Chief Medical Officer
$568.08K$757.02K$1.27M$429.00K$14.69K$3.04M+81%
William E. Rote, Ph.D.
Chief Research Officer
$522.33K$583.11K$738.25K$393.00K$19.77K$2.26M+49%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 497 full-time employees, with most of those based in the United States and a small number outside of the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 1, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 5, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 12, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 18, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 13, 2020Name changeName changed from Retrophin, Inc. to Travere Therapeutics, Inc.
Jul 6, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 6, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 3, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 15, 2014Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 16, 2014Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 4, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 9, 2014ListingRegistration of securities on an exchange (Form 8-A)
Jan 7, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 30, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 15, 2013Late filingNotification of late filing
May 16, 2013Late filingNotification of late filing
Apr 2, 2013Late filingNotification of late filing
Feb 19, 2013Name changeName changed from Desert Gateway, Inc. to Retrophin, Inc.
Dec 19, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 29, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 14, 2011Late filingNotification of late filing

See a number that looks wrong?